Research progress on the application of traditional Chinese medicine in regulating NF-κB signaling pathway for the treatment of ovarian cancer.

Somatic mutations in cervicovaginal samples: assessing their role in ovarian cancer detection and prognosis.

Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer.

Ovarian cancer (OC) is a disease often diagnosed at advanced stages with distant metastasis, which is characterized by the epithelial-mesenchymal transition (EMT) of cells. The aim of the present study was to analyze the target genes of Homo sapiens microRNA 200c-3p (hsa-miR-200c-3p) and their associated proteins, which have a role in the EMT process. The expression level of hsa-miR-200c-3p was analyzed in ovarian tissues obtained from healthy individuals (n=15) and patients with advanced epithelial OC (EOC; n=15). Zinc finger enhancer-box binding homeobox 1 (ZEB1) is one of the target genes of hsa-miR-200c-3p and was identified using in silico methods. The expression level of ZEB1 was analyzed in both groups. ZEB1, vimentin and E-cadherin proteins were analyzed using immunohistochemistry (IHC) in healthy and OC tissues. The expression of hsa-miR-200c-3p was significantly increased in patients with OC (P<0.01). ZEB1 expression decreased significantly in the EOC group (P<0.01). The correlation analysis indicated a strong negative correlation between hsa-miR-200c-3p and the ZEB1 gene (ρ=-0.75; P<0.01). IHC staining revealed that the higher staining intensity of ZEB1 and E-cadherin proteins were found in cancerous tissues compared with healthy ones (P<0.05). However, the intensity and extent of vimentin staining was decreased in cancerous tissues (P<0.05). The decreased expression of ZEB1 is regulated by hsa-miR-200c-3p. The downregulation of ZEB1 may cause insufficient binding to the mRNA of E-cadherin, leading to increased E-cadherin expression. The hsa-miR-200c-3p/ZEB1 loop regulates vimentin and E-cadherin expression in OC. The increased expression level of hsa-miR-200c-3p may also cause mesenchymal-to-epithelial transition in OC cells.

Emerging trends and treatment strategies in ovarian cancer: A comprehensive review.

Smad7 drives cisplatin resistance in ovarian cancer via a PRMT5-dependent mechanism.

Epithelial-mesenchymal transition (EMT) and cellular plasticity in Ovarian cancer.

Human VH-antibody-based CAR T cells targeting folate receptor-alpha show enhanced persistence and reduced T-cell exhaustion against ovarian cancer.

Neutrophil extracellular traps enhance platinum resistance in ovarian cancer via SHP-1 activation.

Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer.

Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy.

Design and synthesis of novel triazole-metronidazole boswellic acid hybrids for ovarian cancer targeting.

Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery.

Nanoformulation-enabled CDDP/ICG combination for synergistic chemotherapy and photothermal therapy of ovarian cancer.

Replication Protein A (RPA), a single-stranded DNA (ssDNA)-binding protein is critically involved in DNA replication, checkpoint regulation and DNA repair. We evaluated RPA1, 2, and 3 sub-units protein expression in 331 ovarian tumours, transcripts in 1287 tumours and bioinformatics in the ovarian TCGA cohort (n = 379). Platinum resistant ovarian cancer cells were depleted for RPA 1 or 2 and tested for cisplatin, olaparib and talazoparib sensitivity. HAMNO (RPA1 protein-protein interaction inhibitor) was tested in sensitive and resistant cells. High nuclear RPA1 and RPA2 protein was significantly associated with high grade serous ovarian cancers (HGSOC), advanced stage, platinum resistance and worse progression free survival (PFS) (all ps <0.05). High RPA1 and RPA2 transcripts also linked with poor PFS. Preclinically, RPA1 or RPA 2 depletion increased sensitivity to cisplatin, olaparib and talazoparib treatment. HAMNO monotherapy was cytotoxic to sensitive and resistant cells. We conclude that RPA directed precision oncology strategy could be a viable strategy in HGSOC.

Machine learning assisted raman spectroscopy for the classification of ovarian cancer cells.

Introduction: Ovarian tumours constitute 3% of all malignancies in women and 30% of all cancers affecting the Female Genital Tract (FGT). Cervical and endometrial cancers have a higher incidence than ovarian cancer. According to GLOBOCAN 2022 (Global Cancer Observatory’s estimates for the year 2022), there were 722,138 ovarian cancer cases worldwide, including 45,333 new cases reported in India. India has the second highest incidence of ovarian cancer globally (6.6%), with the highest rates noted in Pune and Delhi. Immunohistochemical (IHC) markers play a crucial role in subtyping, grading, and assisting in the diagnosis and prognosis of ovarian tumours. Aim: The present study aimed to analyse the histopathological and immunohistochemical expression of ovarian tumours and evaluate the role of IHC in differentiating primary ovarian neoplasms from metastatic tumours. Materials and Methods: The present ambispective two-year cross-sectional study was conducted from January 2023 to December 2024 on 188 cases at Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh, India. Haematoxylin and Eosin (H&amp;E)-stained sections along with IHC-stained slides of ovarian neoplasms were prepared and examined. IHC was performed in 58 cases using common primary markers such as Cytokeratin 7 (CK7), Cytokeratin 20 (CK20), Paired Box Gene 8 (PAX8), and Wilms’ Tumour Gene 1 (WT1) to identify primary ovarian tumours. Secondary markers such as Caudal-Type Homeobox 2 (CDX2), Special Adenine-Thymine-rich SequenceBinding Protein 2 (SATB2), Oestrogen/Progesterone Receptors (ER/PR), and Calretinin were used to differentiate tumours of FGT, Gastrointestinal Tract (GIT), breast, and metastatic origin. Additional markers like Inhibin and Octamer-Binding Transcription Factors (OCT) were used for morphological subtyping of sex cord-stromal and germ cell tumours. Results: Out of the 188 cases, surface epithelial tumours were the most common (149 cases), including 82 benign serous cystadenomas, 24 malignant Serous Carcinomas (SCs), and 22 mucinous cystadenomas. Most metastatic tumours (21 cases) presented with omental nodules and abdominal pain and were predominantly of SC type. IHC was performed on 58 cases using CK7/CK20 followed by WT1 and Napsin A, which helped differentiate ovarian tumours from other genitourinary tract tumours. Of these, 37 cases were confirmed as primary ovarian tumours. These included 24 cases of SC, 4 adult granulosa cell tumours, and one case each of Mucinous Carcinoma (MC), neuroendocrine carcinoma (small cell carcinoma), Sertoli-Leydig cell tumour, seromucinous cystadenoma, borderline serous tumour, and mature cystic teratoma. Conclusion: The most common neoplasms observed were surface epithelial tumours, with benign serous cystadenoma being the predominant type, most frequently affecting women of reproductive age. IHC played a significant role in tumour differentiation, grading, and prognostication.

Immune-priming mechanisms of photodynamic therapy in cervical high-grade squamous intraepithelial lesions and translational implications for ovarian near-infrared photoimmunotherapy.

Evaluation of the Performance of the IOTA ADNEX Model in Discriminating Adnexal Masses Preoperatively: An Ambispective Study.

Emily vs. Lakisha: Quantifying socioeconomic and structural disparities in AI-generated ovarian cancer care plans.